tiprankstipranks
Trending News
More News >

Changmao Biochemical Reports Decreased Revenue and Losses for 2024

Story Highlights
Changmao Biochemical Reports Decreased Revenue and Losses for 2024

Confident Investing Starts Here:

Changmao Biochemical Engineering Co. Ltd. Class H ( (HK:0954) ) just unveiled an update.

Changmao Biochemical Engineering Co. Ltd. reported its annual results for the year ended December 31, 2024, revealing a decrease in revenue to RMB 584,794,000 from RMB 637,078,000 in 2023. The company also reported a reduced loss attributable to shareholders, amounting to RMB 68,243,000 compared to RMB 86,057,000 the previous year. Despite the reduced losses, the board has decided not to recommend the payment of a final dividend for the year. This financial performance reflects ongoing challenges in the company’s operations, impacting its market positioning and stakeholder expectations.

More about Changmao Biochemical Engineering Co. Ltd. Class H

Changmao Biochemical Engineering Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China. The company operates in the biochemical engineering industry, focusing on the production and sale of biochemical products.

YTD Price Performance: -6.00%

Technical Sentiment Signal: Buy

Current Market Cap: €26.19M

For a thorough assessment of 0954 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1